{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LN", "query": { "condition": "LN" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LN&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T09:17:15.126Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06153095", "title": "A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus", "Lupus Nephritis" ], "interventions": [ { "name": "IMPT-514", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Lyell Immunopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-02-15", "completion_date": "2025-01-09", "has_results": false, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-05-22T09:17:15.126Z", "location_count": 3, "location_summary": "Los Angeles, California • San Francisco, California • Iowa City, Iowa", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT06153095" }, { "nct_id": "NCT07085104", "title": "A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus (With and Without Nephritis)", "Idiopathic Inflammatory Myopathy", "Systemic Sclerosis" ], "interventions": [ { "name": "ALLO-329", "type": "GENETIC" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Allogene Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 66, "start_date": "2025-11-13", "completion_date": "2032-10", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-05-22T09:17:15.126Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT07085104" }, { "nct_id": "NCT06839976", "title": "CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "SLE", "Systemic Lupus Erythematosus (SLE)", "CAR T Cell", "CART19", "Cell Therapy", "Lupus", "Lupus Nephritis (LN)" ], "interventions": [ { "name": "CART19", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "12 Years to 29 Years" }, "enrollment_count": 24, "start_date": "2025-05-06", "completion_date": "2030-02-28", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-05-22T09:17:15.126Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06839976" }, { "nct_id": "NCT06429800", "title": "A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lupus Nephritis", "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "ATA3219", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Atara Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2025-04-16", "completion_date": "2025-04-16", "has_results": false, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-05-22T09:17:15.126Z", "location_count": 1, "location_summary": "Thousand Oaks, California", "locations": [ { "city": "Thousand Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06429800" }, { "nct_id": "NCT03645928", "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Squamous Cell Carcinoma of the Head and Neck", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Lifileucel", "type": "BIOLOGICAL" }, { "name": "LN-145", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "LN-145-S1", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nivolumab-relatlimab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2019-05-07", "completion_date": "2026-02-20", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-05-22T09:17:15.126Z", "location_count": 20, "location_summary": "La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03645928" }, { "nct_id": "NCT07107659", "title": "Safety and Efficacy of ONT01 in Lupus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lupus Nephritis (LN)", "Lupus Nephritis - WHO Class III", "Lupus Nephritis - WHO Class IV", "Lupus Nephritis - World Health Organization (WHO) Class III", "Lupus", "SLE", "Systemic Lupus Erythematosus", "Systemic Lupus Erythematosus (Disorder)" ], "interventions": [ { "name": "ONT01 is a small molecule CD11b modulator.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hospital for Special Surgery, New York", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2026-09-04", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2025-11-20", "last_synced_at": "2026-05-22T09:17:15.126Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07107659" }, { "nct_id": "NCT06419205", "title": "A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "IgA Nephropathy", "Lupus Nephritis (LN)", "C3 (Complement Component 3) Glomerulopathy" ], "interventions": [ { "name": "ADX-097", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Q32 Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-06-27", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-04-20", "last_synced_at": "2026-05-22T09:17:15.126Z", "location_count": 5, "location_summary": "Denver, Colorado • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06419205" }, { "nct_id": "NCT06935474", "title": "C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lupus Nephritis (LN)" ], "interventions": [ { "name": "C-CAR168", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AbelZeta Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2026-07", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-05-22T09:17:15.126Z", "location_count": 1, "location_summary": "Rockville, Maryland", "locations": [ { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06935474" }, { "nct_id": "NCT06581198", "title": "A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Erythematosus, Systemic", "Lupus Nephritis" ], "interventions": [ { "name": "rapcabtagene autoleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 179, "start_date": "2024-09-04", "completion_date": "2032-02-06", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-05-22T09:17:15.126Z", "location_count": 15, "location_summary": "Birmingham, Alabama • San Bernardino, California • San Francisco, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Bernardino", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Pablo", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06581198" }, { "nct_id": "NCT06975787", "title": "Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lupus Nephritis (LN)" ], "interventions": [ { "name": "Vonsetamig", "type": "DRUG" }, { "name": "Odronextamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 90, "start_date": "2025-12-22", "completion_date": "2028-07-23", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-22T09:17:15.126Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Houston, Texas", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06975787" } ] }